Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

The research group studied squamous cell carcinoma, a skin cancer that has been linked to RAS mutations, to understand the mechanism behind stem cells ignoring environmental signals. To do so, a ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for cancer, has been making significant strides in its clinical pipeline, particularly in the ...

Professor Karen Gripp and his team from DuPont Hospital studied genetic mutations in H-ras gene which lead to Costello Syndrome, scientists found that the gene mutation occured in germline cells ...

Challenges in patient selection for surgical options in V600E BRAF–mutated metastatic colorectal cancer.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

(B) Incidence of BRAF mutations and co-occurring mutations in any RAS gene. (C) Incidence of co-occurring KRAS and PIK3CA mutations.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

About 20% of patients with RASopathies have HCM; RASopathy-associated HCM is often caused by genetic mutations in the RAS/MAPK signaling pathway, which regulates cell growth and development.